Cargando…
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia
The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized the treatment of chronic myeloid leukemia (CML). However current unmet clinical needs include combating activation of additional survival signaling pathways in persistent leukemia stem cells after long-term TKI ther...
Autores principales: | Laidlaw, Kamilla M.E., Berhan, Samuel, Liu, Suhu, Silvestri, Giovannino, Holyoake, Tessa L., Frank, David A., Aggarwal, Bharat, Bonner, Michael Y., Perrotti, Danilo, Jørgensen, Heather G., Arbiser, Jack L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239504/ https://www.ncbi.nlm.nih.gov/pubmed/27438151 http://dx.doi.org/10.18632/oncotarget.10541 |
Ejemplares similares
-
Liposome-Imipramine Blue Inhibits Sonic Hedgehog Medulloblastoma In Vivo
por: MacDonald, Tobey J., et al.
Publicado: (2021) -
Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells
por: Metts, Jonathan, et al.
Publicado: (2017) -
Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia
por: Wang, Zhengqi, et al.
Publicado: (2021) -
CARDIOGENIC SHOCK WITH IMIPRAMINE
por: Chaudhury, S., et al.
Publicado: (1990) -
TREATMENT BY IMIPRAMINE OF DEAFNESS AND DEPRESSION
por: Srivastava, V.K.
Publicado: (1998)